A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing

Description du projet

Un nouvel appareil de laboratoire démocratisera le séquençage nouvelle génération

Le séquençage nouvelle génération (NGS) est un nouvel outil puissant pour la recherche biologique et clinique. Il demeure toutefois inaccessible et inabordable pour les laboratoires, cliniques et entreprises de taille modeste en raison de la faible reproductibilité des préparations manuelles des bibliothèques, de réactifs coûteux et de la rareté des échantillons biologiques. MAGELIA est une nouvelle plateforme automatisée et miniaturisée de préparation d’échantillons pour le NGS à petite échelle. Cette plateforme entièrement automatisée offre une meilleure reproductibilité et nécessite des volumes d’échantillons de 100 à 1 000 fois plus petits que les volumes traditionnels de NGS. MAGELIA vise à démocratiser le NGS; dans cette phase, le projet entend accélérer la mise sur le marché, augmenter le financement de la commercialisation et toucher une large clientèle potentielle.

Objectif

Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform.
After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market.
To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round.
The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.

Champ scientifique

Programme(s)

Thème(s)

EIC-SMEInst-2018-2020 - SME instrument

Appel à propositions

H2020-EIC-SMEInst-2018-2020

Voir d’autres projets de cet appel

Sous appel

H2020-SMEInst-2018-2020-2

Régime de financement

SME-2 - SME instrument phase 2

Coordinateur

INOREVIA

Contribution nette de l'UE

€ 1 955 100,00

Adresse

29 rue du Faubourg Saint-Jacques
75014 PARIS
France

PME

Oui

Région

Ile-de-France Ile-de-France Paris

Type d’activité

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Liens

Contacter l’organisation

Participation aux programmes de R&I de l'UE

Réseau de collaboration HORIZON

Coût total

€ 2 793 000,00